The FDA, NIH, and CDC will bring together a diverse group of stakeholders to summarize progress toward developing vaccines against fungal diseases, with an emphasis on our current understanding of the epidemiology, biology, and immunology of Valley feverContinue reading
Category Archives: AZBio News
ACA Supercharges Support For Arizona Startups
- New venture programs launched to scale Arizona Innovation Challenge
- Applications for the next round of the Arizona Innovation Challenge opened August 1, 2024 and close August 30, 2024.
Protein Homeostasis May Hold the Key to More Successful Treatment of Heart Disease
Coronary artery disease (CAD) is the most common form of heart disease, the leading cause of death for both men and women. Of the roughly 695,000 people who died from heart disease in 2021, more than 375,000 deaths were attributable to CAD, according to the Centers for Disease Control and Prevention (CDC).Continue reading
James Goulka named President & CEO of Arizona Venture Development Corp (AVC)
As President & CEO, James “Jim” Goulka leads AVC’s initiatives to invest in early-stage technology startups and funds across enterprise, software, consumer, climate-tech, and bio/health tech—all while helping catalyze access to equity capital for underserved founders and communities in Arizona.Continue reading
University of Arizona had record number of inventions in FY24
Tech Launch Arizona, the University of Arizona office that commercializes inventions stemming from university research and innovation, saw a record number of inventions during the 2024 fiscal year.
Between July 1, 2023, and June 30, 2024, TLA received 307 new inventions, up from 298 in fiscal year 2023 and 303 in fiscal year 2022. The office also launched nine startups; executed 72 licenses and options for U of A inventions; filed 367 patents; and had 78 patents issued
C-Path’s Alzheimer’s Consortium Unveils Seminal Methodology to Enhance Alzheimer’s Clinical Trials Using Imaging Biomarkers
TUCSON, Ariz., July 26, 2024 – Critical Path Institute (C-Path) is proud to announce the publication of a new study in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association that was led by its Critical Path for Alzheimer’s Disease (CPAD) consortium. The publication details a method that solves a major obstacle to comparing the findings of investigational tau imaging results across Alzheimer’s disease (AD) clinical trials. Continue reading
20 Years after Landmark FDA Approval, SynCardia Remains World’s Only Commercially Approved Total Artificial Heart
Few total artificial hearts make it to human clinical trials, and only the SynCardia Total Artificial Heart has met the rigorous requirements for commercial approval.Continue reading
BIO5 Celebrates the 18th annual KEYS Research Showcase
The University of Arizona BIO5 Institute hosted the 18th annual KEYS Research Showcase, celebrating the culmination of the KEYS Research Internship for 59 students from 31 Arizona high schools.Continue reading
Dr. Jeff Shuren Announces Plans to Retire from CDRH
“Our center experts and programs help get safe and effective technologies to patients and health care professionals on a daily basis and continue to assure devices are safe and effective once on the market,” says Dr. Shuren. “Rapid technological advances enable us to approve innovations that make a difference in people’s lives. I could not be more proud of my fellow colleagues at CDRH, the family we have built, and what we have accomplished together on behalf of the American public.” (Source)Continue reading
Applications open August 1 2024 for the Flinn Foundation’s Seed Grants to Promote Translational Research Program.
The Flinn Foundation Seed Grants to Promote Translational Research Program awardees each receive a $100,000 grant over 18 months, plus programmatic benefits. At the end of the grant period, up to two of the most successful projects may receive up to an additional $100,000 over the following year.Continue reading